1-20 of 112
Andrzej Jakubowiak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Ben A. Derman, Ajay Major, Sarah Major, Brittany D. Wolfe, Martha Gorski, Jennifer H. Cooperrider, Evangelia Andreatos, Ken Jiang, Karson Buckley, Amanda McIver, Andrew Stefka, Andrzej Jakubowiak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2108–2109.
https://doi.org/10.1182/blood-2022-158643
Published: 2022
Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie
Journal: Blood
Blood (2022) 140 (Supplement 1): 1830–1832.
https://doi.org/10.1182/blood-2022-168930
Published: 2022
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos, Jesús San-Miguel, Michele Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A. Dimopoulos
Journal: Blood
Blood (2022) 140 (Supplement 1): 10157–10159.
https://doi.org/10.1182/blood-2022-163347
Published: 2022
Journal Articles

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Jr., Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10154–10156.
https://doi.org/10.1182/blood-2022-162473
Published: 2022
Journal Articles

DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study ( EM agine/CARTITUDE-6)

Mario Boccadoro, Jesús San-Miguel, Kenshi Suzuki, Niels W.C.J. Van De Donk, Gordon Cook, Andrzej Jakubowiak, Deepu Madduri, Salma Afifi, An-Sofie Stevens, Jordan M. Schecter, William Deraedt, Steven Kuppens, Pankaj Mistry, Lida Pacaud, Erika Florendo, Annemiek Broijl, Francesca Gay, Roberto Mina, Leo Rasche, Philippe Moreau, María-Victoria Mateos, Hermann Einsele, Pieter Sonneveld
Journal: Blood
Blood (2022) 140 (Supplement 1): 4630–4632.
https://doi.org/10.1182/blood-2022-157021
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Ajai Chari, Jonathan L. Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7278–7281.
https://doi.org/10.1182/blood-2022-162339
Published: 2022
Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 388–390.
https://doi.org/10.1182/blood-2022-166494
Published: 2022
Journal Articles

Global Health Status Inadequately Captures Longitudinal Changes in Quality of Life in Patients Receiving Carfilzomib for Multiple Myeloma: Electronic Patient-Reported Outcomes (ePROs) from a Prospective Observational Study

Ajay Major, Nicole Prabhu, Claire Cunningham, Jennifer H. Cooperrider, Hannah Johnston, Evangelia Andreatos, Martha Gorski, Sarah Major, Brittany D. Wolfe, Eric Kruse, Ben A. Derman, Roberto M. Lang, Andrzej Jakubowiak, Jeanne DeCara
Journal: Blood
Blood (2022) 140 (Supplement 1): 12593–12595.
https://doi.org/10.1182/blood-2022-157795
Published: 2022
Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Natalie Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P Laubach, Timothy Martin Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Jr., Bhagirathbhai Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Ken H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10144–10147.
https://doi.org/10.1182/blood-2022-160451
Published: 2022
Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Hani Hassoun, Susanna J. Jacobus, Paul G. Richardson, Jeffrey A. Zonder, Peter M. Voorhees, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Edward Libby, Brandi Reeves, Michael L. Wang, Larry D. Anderson, Jr., Carter Milner, Cristina J. Gasparetto, Mounzer Agha, Abdullah Khan, David Duane Hurd, David Avigan, Caitlin Costello, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Eva Medvedova, Philip L. McCarthy, Robert Z. Orlowski, Omar Nadeem, Jacob P. Laubach, Marcelo C. Pasquini, Sergio A. Giralt, Kelly Masone, Mehmet K. Samur, Aurore Perrot, Philippe Moreau, Herve Avet-Loiseau, Edie A. Weller, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4834–4838.
https://doi.org/10.1182/blood-2022-162741
Published: 2022
Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Rebecca Silbermann, Jacob Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Katharine S. Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 1146–1149.
https://doi.org/10.1182/blood-2022-162313
Published: 2022
Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Matthew Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Christine Cornwell, Kamalika Banerjee, Anand Rotte, Christopher R. Heery, David Avigan, Andrzej Jakubowiak, Michael R. Bishop
Journal: Blood
Blood (2022) 140 (Supplement 1): 7439–7440.
https://doi.org/10.1182/blood-2022-163827
Published: 2022
Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Clinical Trials & Observations
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, María-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood
Blood (2022) 139 (4): 492–501.
https://doi.org/10.1182/blood.2020010439
Published: 2022
Includes: Supplemental data
Journal Articles

Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma

Ben A Derman, Andrew J. Belli, Ching-Kun Wang, Eric Hansen, Spencer S Langerman, Andrzej Jakubowiak, Brian C-H Chiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 3789.
https://doi.org/10.1182/blood-2021-149213
Published: 2021
Journal Articles

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Romanos Sklavenitis-Pistofidis, Ankit K. Dutta, Sylvia Ujwary, Robert A. Redd, Alexandra Savell, Léa Fléchon, François Aguet, Nicholas Haradhvala, Oksana Zavidij, Mark Bustoros, Sabrin Tahri, Tarek H Mouhieddine, Nang K. Su, Lily Ardente, Shankara Anand, Jacalyn Rosenblatt, Jeffrey A. Zonder, James J. Vredenburgh, Adam Boruchov, Manisha Bhutani, Saad Z. Usmani, Jeffrey V. Matous, Andrew J. Yee, Andrzej Jakubowiak, Claudia E. Paba-Prada, Julia Prescott, Jacob P. Laubach, Salomon Manier, Omar Nadeem, Paul G. Richardson, Ashraf Z. Badros, Lorenzo Trippa, Maria-Victoria Mateos, Gad Getz, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 330.
https://doi.org/10.1182/blood-2021-147623
Published: 2021
Journal Articles

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Michael Sebag, Noopur S. Raje, Nizar J. Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Y. Levy, Michael H. Tomasson, Harman Dube, Michael A. Damore, Hoi Ken Lon, Cynthia Basu, Athanasia Skoura, Edward Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P. Chu, Cristina Gasparetto, Andrew P. Dalovisio, Alexander Lesokhin
Journal: Blood
Blood (2021) 138 (Supplement 1): 895.
https://doi.org/10.1182/blood-2021-150519
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021
Journal Articles

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur S. Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina
Journal: Blood
Blood (2021) 138 (Supplement 1): 548.
https://doi.org/10.1182/blood-2021-146518
Published: 2021
Journal Articles

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G. Berdeja, Andrzej Jakubowiak, A. Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Nolen J Perualila, Jedelyn Cabrieto, Benjamin Haefliger, Nichola Erler-Yates, Clare Hague, Carolyn C. Jackson, Vadim Strulev, Tonia Nesheiwat, Lida Pacaud, Philippe Moreau, Hermann Einsele
Journal: Blood
Blood (2021) 138 (Supplement 1): 550.
https://doi.org/10.1182/blood-2021-146200
Published: 2021
Journal Articles

A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Ben A Derman, Ajay Major, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Luis Alcantar, Bernadette M. Libao, Amanda McIver, Evangelia Andreatos, Sarah Major, Brittany Wolfe, Martha Gorski, Theodore G. Karrison, Andrew Stefka, Andrzej Jakubowiak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2759.
https://doi.org/10.1182/blood-2021-151832
Published: 2021